Asia-Pacific Pharmacogenetic Testing Market to 2032
Overview
The Asia-Pacific Pharmacogenetic Testing Market is expected to reach a 2.48 USD Billion by 2032 and is projected to grow at a CAGR of 14.34% from 2025 to 2032.
Revenue, 2024 (USD Billion)
1.15
Forecast, 2032 (USD Billion)
2.48
CAGR, 2024 - 2032
14.34%
Report Coverage
Asia-Pacific
Asia-Pacific Pharmacogenetic Testing Market 2018-2032 USD Billion
Asia-Pacific Pharmacogenetic Testing Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 1.15 USD Billion
- Projected Market Size (2032): 2.48 USD Billion
- CAGR (2025-2032): 14.34%
Key Findings of Asia-Pacific Pharmacogenetic Testing Market
- The Asia-Pacific Pharmacogenetic Testing Market was valued at 1.15 USD Billion in 2024.
- The Asia-Pacific Pharmacogenetic Testing Market is likely to grow at a CAGR of 14.34% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Blood in Sample Segment accounted for the largest share of the market with a revenue of 0.64 USD Billion
- The fastest growing segment CYP2C19 in Gene Segment grew Fastest with a CAGR of 18.65% during the forecast period from 2024 to 2032.
Asia-Pacific Pharmacogenetic Testing Market Scope
Asia-Pacific Pharmacogenetic Testing Market Segmentation & Scope
Application
- Drug Regulation
- Drug Development
- Clinical Practice
Therapeutic Area
- Others
- Neurology
- Oncology
- Gynecology
- Dermatology
- Immunology & Hypersensitivity
- Endocrinology
- Genomics
- Anesthesiology
- Gastroenterology
- Cardiology
Sample
- Saliva
- Blood
Distribution Channel
- Direct-to-Customer Services
- Mail-Order Pharmacies
- Retail Pharmacies
- Hospital Pharmacy
End User
- Others
- Research Centres and Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Healthcare Providers
Drug
- Over-the-Counter Medications
- Vitamins
- Herbal Supplements
- Recreational Drugs
- Nutraceuticals
- Prescription Drugs
Type
- Single Gene Tests
- Array-Based Tests
- Whole Exome Sequencing
- Whole Genome Sequencing
Gene
- Others
- TMPT
- HTR2A/C
- SLC6A4
- D4D4
- DRD3
- ONCOTYPE DX® AND MAMMAPRINT®
- OPRM1
- CYP2D
- HLA-B*5701
- HLA-B*1502
- CYP1A2
- CYP2C9 AND VKORC1
- CYP2D6
- CYP2C19
Asia-Pacific Pharmacogenetic Testing Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2021 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 1.15 USD Billion |
| Market Value in 2032 | 2.48 USD Billion |
| CAGR (2025-2032) | 14.34% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Application,Therapeutic Area,Sample,Distribution Channel,End User,Drug,Type,Gene |
Regional Insights:
-
Leading Market (2024-2032): Asia-Pacific, leading in terms of revenue 1.15 USD Billion in 2024
- Key Country: Japan, leading in terms of revenue with value of 262.65 USD Million in 2024.
Segments and Scope
-
Asia-Pacific Pharmacogenetic Testing Market to 2032, By Application
- Clinical Practice is the largest segment in Asia-Pacific Pharmacogenetic Testing Market to 2032 with a revenue of 533.01 USD Billion in the year 2024.
- Clinical Practice is the Fastest growing segment in Asia-Pacific Pharmacogenetic Testing Market to 2032 with a Growth rate of 14.84 % in forecast period 2025-2032.
-
Asia-Pacific Pharmacogenetic Testing Market to 2032, By Therapeutic Area
- Cardiology is the largest segment in Asia-Pacific Pharmacogenetic Testing Market to 2032 with a revenue of 219.77 USD Billion in the year 2024.
- Cardiology is the Fastest growing segment in Asia-Pacific Pharmacogenetic Testing Market to 2032 with a Growth rate of 18.09 % in forecast period 2025-2032.
-
Asia-Pacific Pharmacogenetic Testing Market to 2032, By Sample
- Blood is the largest segment in Asia-Pacific Pharmacogenetic Testing Market to 2032 with a revenue of 640.07 USD Billion in the year 2024.
- Blood is the Fastest growing segment in Asia-Pacific Pharmacogenetic Testing Market to 2032 with a Growth rate of 14.51 % in forecast period 2025-2032.
-
Asia-Pacific Pharmacogenetic Testing Market to 2032, By Distribution Channel
- Hospital Pharmacy is the largest segment in Asia-Pacific Pharmacogenetic Testing Market to 2032 with a revenue of 534.41 USD Billion in the year 2024.
- Hospital Pharmacy is the Fastest growing segment in Asia-Pacific Pharmacogenetic Testing Market to 2032 with a Growth rate of 14.91 % in forecast period 2025-2032.
-
Asia-Pacific Pharmacogenetic Testing Market to 2032, By End User
- Healthcare Providers is the largest segment in Asia-Pacific Pharmacogenetic Testing Market to 2032 with a revenue of 478.87 USD Billion in the year 2024.
- Healthcare Providers is the Fastest growing segment in Asia-Pacific Pharmacogenetic Testing Market to 2032 with a Growth rate of 15.07 % in forecast period 2025-2032.
-
Asia-Pacific Pharmacogenetic Testing Market to 2032, By Drug
- Prescription Drugs is the largest segment in Asia-Pacific Pharmacogenetic Testing Market to 2032 with a revenue of 376.34 USD Billion in the year 2024.
- Prescription Drugs is the Fastest growing segment in Asia-Pacific Pharmacogenetic Testing Market to 2032 with a Growth rate of 15.54 % in forecast period 2025-2032.
-
Asia-Pacific Pharmacogenetic Testing Market to 2032, By Type
- Whole Genome Sequencing is the largest segment in Asia-Pacific Pharmacogenetic Testing Market to 2032 with a revenue of 563.17 USD Billion in the year 2024.
- Whole Genome Sequencing is the Fastest growing segment in Asia-Pacific Pharmacogenetic Testing Market to 2032 with a Growth rate of 14.90 % in forecast period 2025-2032.
-
Asia-Pacific Pharmacogenetic Testing Market to 2032, By Gene
- CYP2C19 is the largest segment in Asia-Pacific Pharmacogenetic Testing Market to 2032 with a revenue of 176.47 USD Billion in the year 2024.
- CYP2C19 is the Fastest growing segment in Asia-Pacific Pharmacogenetic Testing Market to 2032 with a Growth rate of 18.65 % in forecast period 2025-2032.
Asia-Pacific Pharmacogenetic Testing Market Company Share Analysis
| Company Name |
|
||
| Illumina, Inc. | |||
| Thermo Fisher Scientific Inc. | |||
| QIAGEN | |||
| Sonic Healthcare Limited | |||
| BGI | |||
Asia-Pacific Pharmacogenetic Testing Market Geographical Sales Distribution, 2018-2032 USD Billion
Asia-Pacific Pharmacogenetic Testing Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The Asia-Pacific Pharmacogenetic Testing Market is segmented based on Segmentation Application,Therapeutic Area,Sample,Distribution Channel,End User,Drug,Type,Gene.
Asia-Pacific Pharmacogenetic Testing Market was valued at USD 1.15(Revenue in USD Billion) in 2021.
Asia-Pacific Pharmacogenetic Testing Market is projected to grow at a CAGR of 14.34% during the forecast period of 2024 to 2032.
The Blood segment is expected to dominate the Asia-Pacific Pharmacogenetic Testing Market, holding a largest market share of 0.64 USD Billion in 2024
Asia-Pacific Pharmacogenetic Testing Market Scope
Asia-Pacific Pharmacogenetic Testing Market Segmentation & Scope
Application
- Drug Regulation
- Drug Development
- Clinical Practice
Therapeutic Area
- Others
- Neurology
- Oncology
- Gynecology
- Dermatology
- Immunology & Hypersensitivity
- Endocrinology
- Genomics
- Anesthesiology
- Gastroenterology
- Cardiology
Sample
- Saliva
- Blood
Distribution Channel
- Direct-to-Customer Services
- Mail-Order Pharmacies
- Retail Pharmacies
- Hospital Pharmacy
End User
- Others
- Research Centres and Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Healthcare Providers
Drug
- Over-the-Counter Medications
- Vitamins
- Herbal Supplements
- Recreational Drugs
- Nutraceuticals
- Prescription Drugs
Type
- Single Gene Tests
- Array-Based Tests
- Whole Exome Sequencing
- Whole Genome Sequencing
Gene
- Others
- TMPT
- HTR2A/C
- SLC6A4
- D4D4
- DRD3
- ONCOTYPE DX® AND MAMMAPRINT®
- OPRM1
- CYP2D
- HLA-B*5701
- HLA-B*1502
- CYP1A2
- CYP2C9 AND VKORC1
- CYP2D6
- CYP2C19
Frequently Asked Questions
The Asia-Pacific Pharmacogenetic Testing Market is segmented based on Segmentation Application,Therapeutic Area,Sample,Distribution Channel,End User,Drug,Type,Gene.
Asia-Pacific Pharmacogenetic Testing Market was valued at USD 1.15(Revenue in USD Billion) in 2021.
Asia-Pacific Pharmacogenetic Testing Market is projected to grow at a CAGR of 14.34% during the forecast period of 2024 to 2032.
The estimated market value of the Asia-Pacific Pharmacogenetic Testing Market for final year is USD 2.48 (USD Billion).
Asia-Pacific Pharmacogenetic Testing Market Company Profiling
Frequently Asked Questions
The Asia-Pacific Pharmacogenetic Testing Market is segmented based on Segmentation Application,Therapeutic Area,Sample,Distribution Channel,End User,Drug,Type,Gene.
Asia-Pacific Pharmacogenetic Testing Market was valued at USD 1.15(Revenue in USD Billion) in 2021.
Asia-Pacific Pharmacogenetic Testing Market is projected to grow at a CAGR of 14.34% during the forecast period of 2024 to 2032.
The estimated market value of the Asia-Pacific Pharmacogenetic Testing Market for final year is USD 2.48 (USD Billion).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.